82 related articles for article (PubMed ID: 25119312)
1. Changes in bone mineral density in newly diagnosed testicular cancer patients after anticancer treatment.
Willemse PM; Hamdy NA; de Kam ML; Burggraaf J; Osanto S
J Clin Endocrinol Metab; 2014 Nov; 99(11):4101-8. PubMed ID: 25119312
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of vertebral fractures independent of BMD and anticancer treatment in patients with testicular germ cell tumors.
Willemse PM; Hamdy NA; van Wulften L; van Steijn-van Tol AQ; Putter H; Osanto S
J Clin Endocrinol Metab; 2010 Nov; 95(11):4933-42. PubMed ID: 20702527
[TBL] [Abstract][Full Text] [Related]
3. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?
Cameron DA; Douglas S; Brown JE; Anderson RA
Breast Cancer Res Treat; 2010 Oct; 123(3):805-14. PubMed ID: 20686833
[TBL] [Abstract][Full Text] [Related]
5. Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis.
Ramani VA; Grey BR; Addla SK; Dunham MP; Sangar VK; Clarke NW
Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):247-52. PubMed ID: 18093814
[TBL] [Abstract][Full Text] [Related]
6. Predictors of bone mineral loss in patients with ovarian cancer treated with anticancer agents.
Douchi T; Kosha S; Kan R; Nakamura S; Oki T; Nagata Y
Obstet Gynecol; 1997 Jul; 90(1):12-5. PubMed ID: 9207804
[TBL] [Abstract][Full Text] [Related]
7. Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women.
Sienkiewicz E; Magkos F; Aronis KN; Brinkoetter M; Chamberland JP; Chou S; Arampatzi KM; Gao C; Koniaris A; Mantzoros CS
Metabolism; 2011 Sep; 60(9):1211-21. PubMed ID: 21741057
[TBL] [Abstract][Full Text] [Related]
8. Pattern of bone mineral density in patients with sporadic idiopathic hypoparathyroidism.
Laway BA; Goswami R; Singh N; Gupta N; Seith A
Clin Endocrinol (Oxf); 2006 Apr; 64(4):405-9. PubMed ID: 16584512
[TBL] [Abstract][Full Text] [Related]
9. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
10. Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study.
Durnez A; Paternotte S; Fechtenbaum J; Landewé RB; Dougados M; Roux C; Briot K
J Rheumatol; 2013 Oct; 40(10):1712-8. PubMed ID: 23950191
[TBL] [Abstract][Full Text] [Related]
11. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
13. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
14. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
Miller PD; Delmas PD; Huss H; Patel KM; Schimmer RC; Adami S; Recker RR
Calcif Tissue Int; 2010 Oct; 87(4):305-13. PubMed ID: 20737140
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
16. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis.
Buckley LM; Leib ES; Cartularo KS; Vacek PM; Cooper SM
J Rheumatol; 1997 Aug; 24(8):1489-94. PubMed ID: 9263140
[TBL] [Abstract][Full Text] [Related]
17. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
[TBL] [Abstract][Full Text] [Related]
18. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study.
Krieckaert CL; Nurmohamed MT; Wolbink G; Lems WF
Rheumatology (Oxford); 2013 Mar; 52(3):547-53. PubMed ID: 23221326
[TBL] [Abstract][Full Text] [Related]
19. Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy.
Pérez Ruixo JJ; Zheng J; Mandema JW
J Clin Pharmacol; 2014 May; 54(5):503-12. PubMed ID: 24214315
[TBL] [Abstract][Full Text] [Related]
20. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
